Where one study disagrees with what other studies report for the same models, and what we are doing to resolve each case.
These are automatic leads, not findings of error. Each release, a check compares how every study ranks the models it shares with other studies. It flags a study that reverses the order the others agree on, or whose gap to a shared reference model lies well outside theirs. Different tasks, populations or metrics often explain a flag.
A flag never hides a result. Flagged results stay in every table, page and download, marked Contested. A result is withheld only when a reviewer marks it disputed.
Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MetaLR above LIST-S2 in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks LIST-S2 above MetaLR in 4 of 5 comparisons. No other study gives a verdict, so neither is the outlier.
2 papers rank LIST-S2 above MetaLR in 4 of their 13 comparisons and MetaLR higher in 8; 1 is a tie. Of those papers, Livesey and Marsh 2025 ranks MetaLR higher on its own (7 of 7).
Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks M-CAP above LIST-S2 in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks LIST-S2 above M-CAP in 5 of 6 comparisons. No other study gives a verdict, so neither is the outlier.
2 papers rank LIST-S2 above M-CAP in 5 of their 13 comparisons and M-CAP higher in 8. Of those papers, Livesey and Marsh 2025 ranks M-CAP higher on its own (7 of 7).
Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MetaSVM above LIST-S2 in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks LIST-S2 above MetaSVM in 3 of 4 comparisons. No other study gives a verdict, so neither is the outlier.
2 papers rank LIST-S2 above MetaSVM in 3 of their 13 comparisons and MetaSVM higher in 8; 2 are ties. Of those papers, Livesey and Marsh 2025 ranks MetaSVM higher on its own (7 of 7).